Articles published by Nuvation Bio

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

February 09, 2026

Tickers NUVB

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

December 03, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio to Participate in Upcoming Investor Conferences

November 26, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio to Participate in Upcoming Investor Conferences

October 30, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

October 23, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

October 20, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

September 30, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

September 19, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

September 07, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio to Participate in Upcoming Investor Conferences

August 27, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

August 05, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

July 24, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

June 24, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

June 11, 2025

From Nuvation Bio

Via Business Wire

Tickers NUVB

Nuvation Bio to Present at the Cantor Global Healthcare Conference

September 09, 2024

From Nuvation Bio

Via Business Wire

Tickers NUVB

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.